As the biggest industry-led meeting on novel vector development, the 3rd Annual Next Generation Gene Therapy Vectors Summit (June 27-29, 2023 | Boston, MA) will bring together 100+ key opinion leaders to help solve the safety, efficiency, and scalability challenges of the next generation of vectors. Industry heavyweights such as Novartis, Spark Therapeutics, Capsida Biotherapeutics, […]

The 8th Microbiome Movement Drug Development Summit returns in 2023 as North America's definitive microbiome drug development event - and it's back bigger and better than ever! The microbiome-based therapeutic market is rapidly evolving, and it's more important than ever to showcase the efficacy of microbial-based approaches beyond C. difficile. Discover how drug developers are […]

CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders through more objective, frequent, sensitive, and less invasive measures of movement, speech, and cognition. Returning to Boston, the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit is the only industry-specific meeting dedicated to developing translatable, scalable, and successful digital […]

With more than 300 trials in preclinical and clinical development actively using AAV as their vector of choice, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be. In this context, the 2nd Annual Optimizing AAV Safety Summit […]

The Advanced Wound Care Summit is wound care’s only industry-led forum It’s a chance for senior executives to address shared challenges around innovative product development, build meaningful partnerships, and sharpen their R&D and commercial strategies. Whether an established wound care company, an emerging startup, an SME, a regulator, a payer, or key opinion leader, this […]

The 3rd Annual Tumor Myeloid-Directed Therapies Summit returns with over 75% new speakers to share insights across a range of myeloid targets, including CD40, CD39, LILRB2, CLEC-1 as well as CAR-M therapies. The one-stop shop continues to be your go-to forum to accelerate myeloid therapy progression by determining optimal combination strategy, optimize translational studies, discover […]

Design & Engineer Functional & Manufacturable Novel Fusion Proteins Prepare to be captivated by the Fusion Protein Engineering & Developability Summit, the ultimate event tailored to drug developers with groundbreaking fusion protein pipelines. This conference is an absolute game-changer that should be at the top of your priority list! As the demand for practical and […]

With the exciting news that Novartis has received US FDA approval for Pluvicto for previously-treated patients with PSMA-positive metastatic castration-resistant prostate cancer, the TRP space is continuing to go from strength to strength. This is why the upcoming 2nd Annual Targeted Radiopharmaceuticals Summit US program is even more comprehensive than ever, bringing you a tracked agenda covering the whole TRP landscape from discovery, translation, to clinical, late stage progress and challenges – a unique opportunity for […]

Established industry leaders and emerging innovators such as Adicet Bio, IN8Bio, Sanofi, Merck, LAVA Therapeutics, Takeda and Leucid Bio are driving the race to demonstrate the potential of Gamma Delta T Therapies as cytotoxic, off-the-shelf solid tumor therapies, spurred by early indications of clinical efficacy. The 4th Gamma Delta T Therapies Summit returns to Boston […]

There is a vast number of ADCs that never make it to the clinic let alone to market, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity, their translatability into the clinic, as well as mitigation and dosing strategies to limit these toxicities will enable ADC […]

The 3rd mRNA-Based Therapeutics Summit returns to Boston this July, cementing its position as the world’s only end-to-end meeting focused on the next generation of mRNA-based therapeutics and vaccines. Download the event program here. This year’s meeting promises 75+ deep-dive case studies from a speaker faculty that is 85% new for this year’s agenda, featuring presentations from the FDA, Pfizer, Moderna, BioNTech, Sanofi and many more. Expect 100+ […]